Fast, actionable treatment decisions for NSCLC patients
ASPYRE®-Lung is the first clinical application for ASPYRE®, a new category of rapid, comprehensive biomarker testing. It was specifically created to provide physicians with actionable results within days of diagnosis, enabling rapid identification of the best treatment options.
Fast time to treatment
ASPYRE is a patented molecular chemistry that uses a unique enzymatic reaction to dramatically accelerate the detection of actionable biomarkers from tissue or blood within hours vs. weeks for sequencing technologies.
Ultra-sensitive
ASPYRE is as sensitive and specific as gold standard NGS assays, For DNA: 100% positive and negative percent agreement: For RNA: 100% positive and negative percent agreement.
Reduced sample requirement
ASPYRE’s high sensitivity enables testing from tissue samples with as little as 10% tumor content, as compared to 20% to 30% for most competing assays, minimizing the frustration from not having enough sample to run the assay (QNS) or failure rates for sequencing technologies (QC).
Actionable results
ASPYRE-Lung comprehensive lung panel includes all NCCN guideline recommended genomic biomarkers associated with targeted therapies for NSCLC.
DNA + RNA
ASPYRE-Lung simultaneously analyzes DNA and RNA from blood or tissue in a single assay, maximizing the opportunity to identify mutations and fusions, while avoiding the additional time and expense of running separate assays.
Cost effective
At a fraction of the cost of NGS, ASPYRE was created to increase patient access to biomarker testing, and to minimize the barrier of prior authorization from payors.
Biomarkers included in ASPYRE-Lung
ASPYRE-Lung enables the simultaneous analysis of 77 DNA mutations & 37 RNA fusions.
DNA
EGFR
Exon 18
G719A
G719S
G719C
Exon 19
Deletions
Insertions
Exon 20
T790M
S7681
C797S
Insertions
Exon 21
L858R
L861Q
BRAF
Exon 15
V600E
KRAS
Exon 2
G12A
G12C
G12D
G12F
G12R
G12S
G12V
Exon 2
G13A
G13C
G13D
G13R
Exon 3
Q61E
Q61H
Q61K
Q61L
Q61R
ERBB2
Exon 17
V659E
Exon 20
Insertions
RNA
ALK
RET
MET
NTRK1
NTRK2
NTRK3
ROS1
Featured resources & publications
The ASPYRE technology
Read more about how the unique molecular biology behind ASPYRE overcomes the limitations of PCR and NGS to increase access to comprehensive biomarker testing.
Ultra-sensitive molecular detection of gene fusions from RNA using ASPYRE
Gray et al, BMC Medical Genomics | (2022) 15:215
Single-copy detection of somatic variants from solid and liquid biopsy
A-L. Silva et al, Scientific Reports | (2021) 11:6068
ASPYRE-Lung now available
By simplifying the detection of genomic biomarkers, use of ASPYRE-Lung as a first-line diagnostic helps identify those NSCLC patients who will likely benefit from precision medicine in a fraction of the time and at a fraction of the cost of NGS.
